Treutlein, Christoph
Distler, Jörg H. W.
Tascilar, Koray
Fakhouri, Sara Chenguiti
Györfi, Andrea-Hermina
Atzinger, Armin
Matei, Alexandru-Emil
Dees, Clara
Büttner-Herold, Maike
Kuwert, Torsten
Prante, Olaf
Bäuerle, Tobias
Uder, Michael
Schett, Georg
Schmidkonz, Christian
Bergmann, Christina http://orcid.org/0000-0001-5257-9171
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (DI 1537/13-1, DI 1537/14-1, DI 1537/17-1, DI 1537/20-1, DI 1537/22-1, BE 7036/2-1)
IZKF Erlangen (grant 21-11-09-1-Bergmann, Clinician Scientist Program)
Universitätsklinikum Erlangen
Article History
Received: 22 September 2022
Accepted: 3 December 2022
First Online: 16 December 2022
Declarations
:
: The study was performed in accordance with the Declaration of Helsinki, and all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee. Subjects were enrolled in the study after signing the informed consent form.
: JHWD has consultancy relationships and/or has received research funding from Actelion, BMS, Celgene, Bayer Pharma, Boehringer Ingelheim, JB Therapeutics, Sanofi-Aventis, Novartis, UCB, GSK, Array Biopharma, Galapagos, Inventiva, and Active Biotech in the area of potential treatments of SSc and is stock owner of 4D Science. CB has received consultancy fees from Pfizer, Janssen, and Boehringer Ingelheim. KT has received consultancy fees and honoraria from UCB and Gilead. CS has received consultancy fees from ROTOP Pharmaka GmbH and Lilly Pharmaceuticals.